Affiliations: [a] Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China | [b] SurExam Bio-Tech Co., Guangzhou, Guangdong, China
Correspondence:
[*]
Corresponding author: Lifen Ren-Heidenreich, PhD, Global Chief Scientific Officer, SurExam Bio-Tech Co., Guangzhou Technology Innovation Base, 80 Lanyue Road, Science City, Guangzhou 510663, China. http://www.surexam.com/, My US Mobile: 401 206 2931; Fax: +86 20 3205 7122; E-mail: lifen.ren@surexam.com/lifenren@yahoo.com.
Abstract: The prevalence of EGFR, KRAS, BRAF and PIK3CA somatic mutations in 861 randomly selected Chinese patients with non-small cell lung cancer (NSCLC) was assayed by the SurPlex®-xTAG70plex platform and analyzed. The results showed that the occurrence rates were 41.0, 8.0, 0.7 and 3.7%, respectively. The mutation rates significantly correlated with gender, histology and smoking history. The EGFR exon 19, 20 and 21 mutations were higher in females compared to males (p< 0.001, exon 19 and 21; p=0.018, exon 20), higher in adenocarcinomas compared to other forms of lung cancers (p< 0.001, exon 19 and 21; p=0.035, exon 20), and higher in non-smokers compared to smokers (p< 0.001, exon 19 and 21; p=0.029, exon 20). Conversely, the KRAS mutations were higher in males compared to females (p=0.004), higher in adenocarcinomas compared to other forms of lung cancers (p< 0.001), and higher in smokers compared to non-smokers (p< 0.001). The PIK3CA mutation rate was lower in adenocarcinomas compared to other forms of lung cancers (p=0.003).
